Company intelligence / Profile preview
Pure Green Pharmaceuticals
Inkster / West Bloomfield*, Michigan, United Statespgpharma.co ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Pure Green Pharmaceuticals is conducting a randomized, double-blind, placebo-controlled Phase 1/2 trial evaluating a combination of cannabidiol and palmitoylethanolamide for the treatment of painful diabetic peripheral neuropathy. The company aims to develop pharmaceutically precise, targeted cannabis-based medicines with an emphasis on scientific rigor and clinical validation. Clinical results have not yet been published.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules (cannabinoids)Combination therapies (e.g., cannabidiol and palmitoylethanolamide)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Pure Green Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pure Green Pharmaceuticals.